Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule, according to a DEFA14A notice. The materials are related to the company's upcoming proxy statements pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing, which is not preliminary and does not require a filing fee, indicates that Pfizer is preparing for matters related to its corporate governance that will be addressed in the proxy statement. This is a routine filing for the company and is part of the standard process of engaging with shareholders on governance issues.

Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule, according to a DEFA14A notice. The materials are related to the company's upcoming proxy statements pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing, which is not preliminary and does not require a filing fee, indicates that Pfizer is preparing for matters related to its corporate governance that will be addressed in the proxy statement. This is a routine filing for the company and is part of the standard process of engaging with shareholders on governance issues.